Jump To Jump To Watch More Videos & Webinars The Promise Registry: How Genetic Factors Impact Prostate Cancer August 19, 2022 We know that prostate cancer may be written in some genetics, but so are instructions for discovering new treatments and understanding family risk. Join Dr. Heather Cheng and Dr. Channing Paller live as they talk about the PROMISE Study Registry, a research study led by physicians from Johns Hopkins University and University of Washington. This observational study enables men with prostate cancer to find out if they have genetic factors that may influence their disease and treatment options.Watch The PROMISE registry seeks to learn more about the role genes can play in improving outcomes and/or treatments for prostate cancer patients. This registry will help us understand how prostate cancer care can be tailored precisely based on a patient’s unique genetic profile. This means better information, testing, and choices. The PROMISE registry will enable us to examine how information about genetic profiles can:Influence the susceptibility of men to prostate cancerImpact the effectiveness of existing treatmentsImprove guidance for different and/or new treatment optionsSuggest precise areas to explore for new discoveries. How PROMISE works PROMISE is completely free. Patients continue with their current provider and don’t even need to leave home to participate. Patients register online. They receive a simple home-based saliva sample DNA test kit. The kit will screen for one of 30 cancer risk genes. Patients will receive results and will be provided access to a licensed genetic counselor to help them understand the findings. Stringent measures are in place to ensure safety, privacy, and security.Benefits of joining the PROMISE study Prostate cancer patients who join PROMISE will: Receive free genetic testing and counseling; gain valuable information about genetic factors in cancer; and discover if they have a critical gene mutation that may impact their care plan. Receive the most current information about new research, clinical trial opportunities, and treatments approved by the FDA. Help family members understand their own risk of cancer and risk for future generations. Make an important contribution to advancing research and understanding of prostate cancer by providing essential genetic information and long-term outcomes that are not available anywhere else. Learn moreTo learn more about the Promise Prostate Cancer study visit ProstateCancerPromise.org, pcctcpromise@mskcc.org, or call 646-449-3363. With your help we can win the fight against prostate cancer. More videos & webinars Learning about your prostate cancer diagnosis is important. Our content library covers topics from diagnosis to treatment options, support for caregivers, navigating financial barriers, and more. More Videos & Webinars About Prostate Cancer Clinical Trials Genetic Testing Treatment Options Videos & Webinars Contributors Shelby Moneer, Vice President, Patient Programs & Education Shelby Moneer was the Vice President of Patient Programs & Education at ZERO Prostate Cancer until April 2025. Heather Cheng MD, PhD, Associate Professor Dr. Cheng is an associate professor, Division of Medical Oncology, Department of Medicine, University of Washington. She is also a faculty member at Fred Hutchinson Cancer Research Center. Dr. Cheng is a lead investigator of the PROMISE study. She focuses on improving the care of patients with prostate and bladder cancers. An expert in prostate cancer genetics, Dr. Cheng often provides content For ZERO Prostate Cancer. Dr. Cheng is studying ways to use genetics to guide the care of prostate cancer patients and their family members who may also be at high risk for the disease. She leads clinical trials of a variety of new treatments for prostate cancer. Dr. Cheng led the research study: GENTleMEN: GENetic Testing for MEN with metastatic prostate cancer. She is also developing new tests that could help guide doctors’ choice of treatment for each patient and new blood tests to detect and monitor the progression of prostate cancer. Dr. Channing Paller Dr. Paller is associate professor of Oncology and Urology at Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center and associate director for Oncology of the Johns Hopkins Clinical Research Network. She is a clinician scientist focused on translating basic scientific findings into treatments that will improve clinical outcomes and reduce toxicities for men with prostate cancer. Dr. Paller is a lead investigator of the PROMISE study and, as an expert in clinical trial design, she leads multiple clinical trials of innovative new treatments and treatment combinations employing germline and somatic biomarkers. She earned her M.D. at Harvard Medical School and completed her medical residency and fellowship in Medical Oncology at Johns Hopkins. More for you
We know that prostate cancer may be written in some genetics, but so are instructions for discovering new treatments and understanding family risk. Join Dr. Heather Cheng and Dr. Channing Paller live as they talk about the PROMISE Study Registry, a research study led by physicians from Johns Hopkins University and University of Washington. This observational study enables men with prostate cancer to find out if they have genetic factors that may influence their disease and treatment options.Watch
The PROMISE registry seeks to learn more about the role genes can play in improving outcomes and/or treatments for prostate cancer patients. This registry will help us understand how prostate cancer care can be tailored precisely based on a patient’s unique genetic profile. This means better information, testing, and choices. The PROMISE registry will enable us to examine how information about genetic profiles can:Influence the susceptibility of men to prostate cancerImpact the effectiveness of existing treatmentsImprove guidance for different and/or new treatment optionsSuggest precise areas to explore for new discoveries. How PROMISE works PROMISE is completely free. Patients continue with their current provider and don’t even need to leave home to participate. Patients register online. They receive a simple home-based saliva sample DNA test kit. The kit will screen for one of 30 cancer risk genes. Patients will receive results and will be provided access to a licensed genetic counselor to help them understand the findings. Stringent measures are in place to ensure safety, privacy, and security.Benefits of joining the PROMISE study Prostate cancer patients who join PROMISE will: Receive free genetic testing and counseling; gain valuable information about genetic factors in cancer; and discover if they have a critical gene mutation that may impact their care plan. Receive the most current information about new research, clinical trial opportunities, and treatments approved by the FDA. Help family members understand their own risk of cancer and risk for future generations. Make an important contribution to advancing research and understanding of prostate cancer by providing essential genetic information and long-term outcomes that are not available anywhere else. Learn moreTo learn more about the Promise Prostate Cancer study visit ProstateCancerPromise.org, pcctcpromise@mskcc.org, or call 646-449-3363. With your help we can win the fight against prostate cancer.
More videos & webinars Learning about your prostate cancer diagnosis is important. Our content library covers topics from diagnosis to treatment options, support for caregivers, navigating financial barriers, and more. More Videos & Webinars
